Scientists in Salford, U.K., have identified a gene that is “revving the engine of cancer” against the world’s most common breast cancer drug. For reasons unknown, 50 percent of patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment. In a paper published in the journal Oncotarget, biochemists…